62. Tackling autoimmune and allergic disease, Jonathan Rigby, Group CEO, Revolo Biotherapeutics

62. Tackling autoimmune and allergic disease, Jonathan Rigby, Group CEO, Revolo Biotherapeutics

Jonathan Rigby is an experienced CEO with three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry. He currently serves as the CEO of Revolo Biotherapeutics, a biotechnology company setting out to revolutionize the treatment for autoimmune and allergic diseases, through the development of therapies that reset the immune system to achieve superior long-term disease remission. Prior to leading the charge at Revolo, Mr. Rigby established SteadyMed Therapeutics Inc. and focused the company on the development of drug device combination products to treat Pulmonary Hypertension. As the CEO, he led the company through a Nasdaq listing in 2015(Nasdaq: STDY) and a public-to-public company sale to United Therapeutics (Nasdaq: UTHR)in late 2018. In 2006 he co-founded Zogenix, Inc. (Nasdaq: ZGNX) a specialty pharmaceutical company now focused on the development and commercialization of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010. Earlier in his career, Jonathan held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics, now Phillips Medical. Jonathan has served as Executive Board Member at SteadyMed Ltd. (Nasdaq: STDY), Non-Executive Board Member at Xeris Pharmaceuticals (Nasdaq: XERS) and Chairman of the Board at CollPlant Biotechnologies (Nasdaq: CLGN). He holds a Bachelor of Science Degree with Honors in Biological Sciences from Sheffield University, UK, and an MBA from Portsmouth University, UK.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Juni 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Maj 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Apr 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Mars 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Mars 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Feb 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Feb 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Jan 21min

Populärt inom Vetenskap

p3-dystopia
dumma-manniskor
allt-du-velat-veta
medicinvetarna
rss-ufobortom-rimligt-tvivel
kapitalet-en-podd-om-ekonomi
rss-vetenskapsradion-2
rss-kriminologerna
rss-vetenskapsradion
svd-nyhetsartiklar
rss-spraket
sexet
bildningspodden
vetenskapsradion
rss-ronden
dumforklarat
rss-broccolipodden-en-podcast-som-inte-handlar-om-broccoli
rss-lara-fran-larda-en-fackbok-och-en-forfattare
rss-odla
naturmorgon